Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

KTTA stock hub

Pasithea Therapeutics Corp. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

KTTAis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

19.8M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

KTTA

In the news

Latest news · KTTA

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.6P50 18.3P75 33.7

Trailing P/En/a

P25 15P50 23.3P75 38.5

ROE-58.4

P25 -106.6P50 -46.9P75 -3.1

ROIC-29.8

P25 -63.1P50 -27.5P75 -0

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All KTTA market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

170

Groups with data

Currency

USD

Showing 170 of 170 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001841330
Company name	Pasithea Therapeutics Corp.
Country	United States
Country code	US
Cusip	70261F103
Employees	5
Employees Change	1%
Employees Change Percent	25
Enterprise value	$-35.3M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2021-09-15
Isin	US70261F2020
Last refreshed	2026-05-10
Market cap	$19.8M
Market cap category	Nano-Cap
Price	$0.8
Price currency	USD
Sector	Healthcare
Sic	2834
Symbol	KTTA
Website	https://www.pasithea.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-102.99%
FCF yield	-76.69%
P/B ratio	0.33x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-20.4M
Net Income Growth Years	0%
Profit Per Employee	$-4.1M
ROA	-27.35
Roa5y	-24.82
ROCE	-30.21
ROE	-58.36
Roe5y	-42.33
ROIC	-29.81

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-29.64%
Cagr3y	-50.6%
EPS Growth Quarters	5
EPS Growth Years	2
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$60.2M
Cash	$55.2M
Current Assets	$56.5M
Current Liabilities	$5M
Equity	$55.2M
Liabilities	$5M
Long Term Assets	$3.8M
Long Term Liabilities	$46,871
Net Cash	$55.2M
Net Cash By Market Cap	$278
Net Cash Growth	696.78%
Net Debt Equity	$-1
Tangible Book Value	$51.4M
Tangible Book Value Per Share	$2.23
WACC	5.48

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	11.35
Net Working Capital	$-3.7M
Quick ratio	11.09
Working Capital	$51.5M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-541.47%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-29.62%
200-day SMA	0.81
3Y total return	-87.95%
50-day SMA	0.77
50-day SMA vs 200-day SMA	50under200
All Time High	170
All Time High Change	-99.53%
All Time High Date	2021-11-23
All Time Low	0.28
All Time Low Change	183.02%
All Time Low Date	2025-11-21
ATR	0.06
Beta	0.22
Beta1y	10.03
Beta2y	4.03
Ch YTD	-38.35
High	0.84
High52	2.06
High52 Date	2025-11-28
High52ch	-61.39%
Low	0.79
Low52	0.28
Low52 Date	2025-11-21
Low52ch	183.03%
Ma50ch	2.71%
Price vs 200-day SMA	-2.41%
RSI	54.23
RSI Monthly	29.48
RSI Weekly	47.51
Sharpe ratio	0.32x
Sortino ratio	0.83
Total Return	-541.47%
Tr YTD	-38.35
Tr1m	-0.34%
Tr1w	-5.43%
Tr3m	9.7%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	1
Analyst Ratings	Strong Buy
Earnings EPS Estimate	$-0.45
Operating Income	$-16.7M
Price target	$3
Price Target Change	$277

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	10,202,043%
Float Percent	40.91%
Shares Insiders	1.49%
Shares Institutions	26.58%
Shares Out	24,939,948
Shares Qo Q	71.57%
Shares Yo Y	541.47%
Short Float	2.23%
Short Ratio	0.34
Short Shares	0.91

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-15.5M
Average Volume	453,322.1x
Bv Per Share	2.39
Ch1m	-0.34
Ch1w	-5.43
Ch1y	-29.62
Ch3m	9.7
Ch3y	-87.95
Ch6m	15.26
Change	-5.32%
Change From Open	-4.55
Close	0.84
Days Gap	-0.81
Depreciation Amortization	662,585
Dollar Volume	149,291.3
Earnings Date	2026-05-22
Earnings Time	amc
EBIT	$-16.7M
EBITDA	$-16M
EPS	$-2.91
F Score	2
FCF	$-15.2M
FCF EV Yield	43.06x
FCF Per Share	$-0.61
Financing CF	63,518,800
Fiscal Year End	December
Founded	2,020
Investing CF	11,000
Ipr	-84.09
Iprfo	-99.01
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-30
Last Report Date	2025-12-31
Last Split Date	2024-01-02
Last Split Type	Reverse
Last10k Filing Date	2026-03-30
Ma150	0.84
Ma150ch	-5.32%
Ma20	0.75
Ma20ch	5.79%
Net CF	48,337,076
Next Earnings Date	2026-05-22
Open	0.83
Optionable	No
Position In Range	5.31
Post Close	0.8
Postmarket Change Percent	0.59
Postmarket Price	$0.8
Price Date	2026-05-08
Ptbv Ratio	0.39
Relative Volume	0.41x
Share Based Comp	297,467
Tr6m	15.26%
Us State	Florida
Volume	187,717

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does KTTA pay a dividend?

Capital-return profile for this ticker.

Performance

KTTA stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns KTTA?

Insider, institutional, and short-interest positioning.

Institutional ownership

+26.6%

Float: +40.9% of shares outstanding

Insider ownership

+1.5%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

KTTA momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

54.2

Neutral momentum band

Price vs 200-day MA

-2.4%

50/200-day relationship not available

Beta (5Y)

0.22

Less volatile than the market

Sharpe ratio

0.32

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About KTTA

Hub-level FAQ points readers to the deeper analysis pages.

What is the current KTTA stock rating?

Pasithea Therapeutics Corp. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full KTTA analysis?

The full report lives at /stocks/KTTA/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for KTTA?

The latest report frames KTTA around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the KTTA page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.